• Verona Pharma Updates Clinical Development of COPD Therapy RPL554
  • European Union Approves Chiesi’s COPD Maintenance Therapy Trimbow
  • RPL554 Administered to First Patients in Phase 2b Clinical Study for COPD Treatment
  • Novavax’s Lung Virus Vaccine Provokes Immune Response, Reduces COPD Hospitalizations, Trials Show
  • Phase 3 Trial Demonstrates Improved Safety Profile of Revefenacin for Moderate to Very Severe COPD
  • Pulmonary Structural Changes Regulate Lung Bacteria in COPD Patients, Study Finds
  • Sunovion Divesting U.S. Market Rights to Asthma and Allergic Rhinitis Therapies to Covis Pharma
  • Cytokinetics Launches Phase 1b Trial for COPD Therapy Candidate CK-2127107
  • Positive Airway Pressure Therapy Might Reduce COPD Hospitalizations, But Few Patients Receive It
  • FDA Agrees to New Review of the SUN-101/e-Flow COPD Treatment System
  • Verona Gets Green Light to Enroll Patients in European Trial of COPD Therapy RPL554
  • UK’s National Health Service Approves Daxas as Treatment for COPD